BridgeBio Pharma Inc ATTRibute-CM Phase 3 Transcript
Good day, and thank you for standing by. Welcome to today's discussion with BridgeBio, which will cover the company's ATTRibute-CM Phase III results as presented at ESC. Currently, all participants are in a listen-only mode. Please be advised that today's conference is being recorded.
I would now like to introduce you to the speakers for today: Julian Gillmore, MD-PhD Professor at University College London and Head of University College London Center for amyloidosis and [asomyloidosis] center research fleet; Jonathan Fox, MD-PhD Chief Medical Officer of BridgeBio Cardio Renal.
I will now hand the call over to Neil Kumar, PhD, CEO of BridgeBio. Please go ahead.
Thank you, operator, and thanks, everyone, for joining. The team has assembled here in Amsterdam, where we had the privilege of sharing further details from our ATTRibute-CM Phase III clinical trial results of acoramidis and ATTR cardiomyopathy. I used the word privilege on multiple levels. Number one, that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |